Lecture Notes

**Lecture Coverage:**
- Rheumatoid Arthritis
- NSAIDs
- Slow Acting Anti-Rheumatic Drugs (SAARDs)
- Glucocorticoids
- New Antirheumatic Drugs

---
#### **Rheumatoid Arthritis**
- Synovitis from Immunoresponse against Joint Tissue
	- Severe joint stiffness, swelling & deformities with pain
    - Through Pro-Inflammatory cytokines:
	    - IL-1/2
	    - TNF-α
- Causes:
	- Genetic
	- Environmental Factors
	- Acute Trigger (Trauma / Infection)
- Treatment Aim:
	- Symptom Relief
	- Lifestyle Preservation
	- Prevention of Structural Damage & Dysfunction


#### **NSAIDs**
- Pain Relief Only ([[Lecture 8.1 - Pain & Analgesics#**Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)**|Mechanism]])
	- Need Higher Dose & Longer Duration than Simple Analgesia
		- High chance of side effects (esp. GI)
		- Paracetamol: Less side effect risk but very weak anti-inflammatory effect
- Does not Alter Disease Course


#### **Slow Acting Anti-Rheumatic Drugs (SAARDs)**
**Advantages & Disadvantages of SAARDs**
- Advantages:
	- May retard disease progress
	- Beneficial in Progressive RA 
		- ∵ Poor response to NSAIDs
	- ↓ Pain & Swelling
- Disadvantages:
	- Does not completely halt RA
	- Slow-Acting: ~6 Weeks before Improvement is shown
	- Side Effects:
		- Immunodeficiency
		- Hyperglycemia & Dyslipidemia → Hypertension
		- Peptic, Liver & Kidney Injury

**Methotrexates (MTX)**
- Oral / Injection
- Inhibitor of several nucleotide synthesis enzymes
	- Suppress Mitosis & Inflammation
	- Different actions in different leukocytes:

|            Cell Type            |                                              Role                                               |                                                   Significance                                                   |
| :-----------------------------: | :---------------------------------------------------------------------------------------------: | :--------------------------------------------------------------------------------------------------------------: |
|           <br>T Cell            |         ↑ <abbr Title="Long Intergenic Non-Coding RNA-21">lincRNA-21</abbr> Expression          |                                                        <                                                         |
|                ^                |                   <abbr Title="Dihydrofolate Reductase">DHFR</abbr> Inhibitor                   | ↓ <abbr Title="Dihydrobiopterin">BH<sub>2</sub></abbr> → <abbr Title="Tetrahydrobiopterin">BH<sub>4</sub></abbr> |
|            Monocyte             |                   <abbr Title="Dihydrofolate Reductase">DHFR</abbr> Inhibitor                   |               ↓ <abbr Title="Dihydrofolate">DHF</abbr> → <abbr Title="Tetrahydrofolate">TTF</abbr>               |
| Fibroblast-Like<br>Synoviocytes | <abbr Title="Aminoimidazole-4-Carboxamide Ribonucleotide">AICAR</abbr> Transformylase Inhibitor |           ↑ Intracellular AICAR<br>↑ <abbr Title="Anti-Inflammatory Mediator">Adenosine</abbr> Release           |

**Hydroxychloroquine**
- ↓ Production of Pro-inflammatory Cytokines
	- Different actions on different leukocytes:

|    Location    |                        Role                         |  Significance  |
| :------------: | :-------------------------------------------------: | :------------: |
| <br>T & B Cell |                    ↓ Activation                     |       <        |
|       ^        |      T<sub>reg</sub>/Th17 Cell Ratio Balancing      |       <        |
|      APC       |               ↓ Antigen Presentation                |       <        |
|   Neutrophil   | ↓ <abbr Title="NADPH Oxidase">NOX</abbr> Signalling | ↓ Phagocytosis |

**Sulphasalasine**
- Prodrug that splits into 2 Parts:
	- Sulphapyridine
		- Anti-bacterial
		- 